Valeo Financial Advisors LLC Buys Shares of 385 argenx SE (NASDAQ:ARGX)

Valeo Financial Advisors LLC bought a new stake in argenx SE (NASDAQ:ARGX – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 385 shares of the company’s stock, valued at approximately $237,000.

Several other large investors also recently bought and sold shares of the company. SG Americas Securities LLC grew its holdings in argenx by 6.2% in the fourth quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock valued at $220,000 after purchasing an additional 21 shares during the last quarter. Choreo LLC boosted its stake in shares of argenx by 4.4% during the fourth quarter. Choreo LLC now owns 551 shares of the company’s stock valued at $342,000 after acquiring an additional 23 shares during the last quarter. Raymond James Trust N.A. boosted its stake in shares of argenx by 6.0% during the third quarter. Raymond James Trust N.A. now owns 495 shares of the company’s stock valued at $268,000 after acquiring an additional 28 shares during the last quarter. Hantz Financial Services Inc. boosted its stake in shares of argenx by 8.9% during the third quarter. Hantz Financial Services Inc. now owns 528 shares of the company’s stock valued at $286,000 after acquiring an additional 43 shares during the last quarter. Finally, Aaron Wealth Advisors LLC boosted its stake in shares of argenx by 10.1% during the fourth quarter. Aaron Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $301,000 after acquiring an additional 45 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on ARGX shares. JPMorgan Chase & Co. increased their price objective on argenx from $640.00 to $670.00 and gave the company an “overweight” rating in a research note on Monday, November 4th. Scotiabank raised argenx from a “sector perform” rating to a “sector outperform” rating and increased their price objective for the company from $439.00 to $715.00 in a research note on Tuesday, November 5th. Wedbush reissued an “outperform” rating and issued a $655.00 price target on shares of argenx in a research note on Tuesday, December 3rd. JMP Securities raised their price target on argenx from $606.00 to $696.00 and gave the stock a “market outperform” rating in a research note on Tuesday, January 14th. Finally, HC Wainwright reissued a “buy” rating and issued a $717.00 price target (up from $670.00) on shares of argenx in a research note on Tuesday, January 14th. One analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $658.39.

Want More Great Investing Ideas?

View Our Latest Stock Analysis on ARGX

argenx Stock Performance

Shares of NASDAQ:ARGX opened at $639.00 on Wednesday. The company has a market cap of $38.83 billion, a P/E ratio of -726.14 and a beta of 0.58. argenx SE has a one year low of $349.86 and a one year high of $678.21. The business’s 50-day simple moving average is $640.74 and its 200 day simple moving average is $584.63.

argenx Company Profile

(Free Report)

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.